Role of her3 signaling pathways in er+ and her2+breast cancers

被引：0
|
作者：
Mishra, Rosalin [1 ]
Alanazi, Samar [1 ]
Patel, Hima [1 ]
Yuan, Long [1 ]
Garrett, Joan T. [1 ]
机构：
[1] Univ Cincinnati, Coll Pharm, Cincinnati, OH USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-389
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Patient-derived HER3 mutations transform ER+ and HER2+breast cancer cells via MAPK pathway activation
    Mishra, Rosalin
    Alanazi, Samar
    Yuan, Long
    Solomon, Thomas
    Thaker, Tarjani M.
    Jura, Natalia
    Garrett, Joan T.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
    Avisek Majumder
    Manbir Sandhu
    Debarko Banerji
    Veronica Steri
    Adam Olshen
    Mark M. Moasser
    Scientific Reports, 11
  • [4] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
    Majumder, Avisek
    Sandhu, Manbir
    Banerji, Debarko
    Steri, Veronica
    Olshen, Adam
    Moasser, Mark M.
    SCIENTIFIC REPORTS, 2021, 11 (01) : 9091
  • [5] Outcome of small node-negative ER+/HER2+and ER-/HER2+breast cancers might be different
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (01): : 583 - 583
  • [6] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [7] The role of HER3 in HER2-amplified cancers other than breast cancers
    Majumder, Avisek
    Steri, Veronica
    Salangsang, Fernando
    Moasser, Mark
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Signaling Pathways Activated in Her 2 and ER Negative Breast Cancers
    Song, D.
    Gao, L.
    Cui, M.
    Han, B.
    Zhao, G.
    Fu, T.
    Li, P.
    Ye, F.
    Fan, M. Z.
    Pelletier, G.
    Zhang, D. Y.
    CANCER RESEARCH, 2010, 70
  • [9] Therapeutic targeting of Rac GTPases in ER+ and HER2+breast cancer
    Hampsch, R. A.
    Shee, K.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [10] ER+/HER2+AND ER-/HER2+BREAST CANCERS ARE MOLECULARLY DISTINCT BUT IMMUNE GENE SIGNATURES ARE PROGNOSTIC AND PREDICTIVE IN BOTH GROUPS
    Iwamoto, T.
    Pusztai, L.
    Matsuoka, J.
    Callari, M.
    Kelly, C. M.
    Qi, Y.
    Motoki, T.
    Taira, N.
    Santarpia, L.
    Doihara, H.
    Gianni, L.
    Bianchini, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 74 - 75
12345